DNLI - Denali Therapeutics Inc.
Engineers Gate Manager LP lifted its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 256.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,430 shares of the company's stock after purchasing an additional 41,320 shares during the
WINTON GROUP Ltd decreased its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 80.2% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 14,100 shares of the company's stock after selling 57,079 shares during the period. WINTON GROUP Ltd's holdings in Denali Therapeutics were worth $363,000
Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation. Analyst Ratings This is a breakdown of current recommendations
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. bought a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,026,413 shares of the company's stock, valued at approximately $360,759,000. BlackRock Inc. owned about 8.84% of Denali Therapeutics at the end
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. However, AVLAYAH's US label limits its near-term potential. Zafinofusp alfa and four TV-enabled 2027 readouts provide meaningful pipeline upside beyond AVLAYAH.
Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Analyst Recommendations This is a summary of recent recommendations
Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets.
On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Denali Therapeutics Inc (NASDAQ: DNLI) at a traded price of $25.7
California State Teachers Retirement System increased its position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) by 25.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 162,576 shares of the company's stock after acquiring an additional 33,167 shares during the
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics NASDAQ: DNLI reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer's disease programs into clinical development.
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago.
Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer's disease programs now in clinical development $195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30, 2026, on Thursday, August 6, 2026.
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the opening plenary address, titled “Accelerating the Discovery and Development of Medicines for Neurodegeneration,” at the Alzheimer's Association International Conference® (AAIC), taking place July 12-15 in London. Dr. Watts will discuss recent scientific advances and future opportunities including new insights in the biology of disease, the use of biomarkers for diagnosis and assessment of treatment effect, and the potential for therapeutics to cross the blood-brain barrier for enhanced delivery to the brain.
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.